IBRX-042 In Participants With HPV-Associated Tumors
← catalyst calendarNCT05976828 · readout in 379 d
Sponsored by ImmunityBio, Inc. (industry) · IBRX — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
12estimated
Sites
3
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-06-14 | actual | When the study began enrolling |
| Primary completion | 2027-09-02 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2033-08-14 | estimated | The whole study's end, after follow-up |
| First posted | 2023-08-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- HPV-Related Carcinoma
Intervention
- Drug: IBRX-042 — also filed as IBRX-042 (hAd5-HPV E6.ETSD-IRES-E7.ETSD Vaccine)
Primary outcome
what the primary-completion date above is the date OFDetermine the maximum tolerated dose of IBRX-042
measured 1 year
Permalink · IBRX's whole pipeline · Catalyst calendar · Every registered study · What changed